BioStabilization Systems (BoSS)

The BioStabilization Systems (BoSS) program aims to transform how live cell-based therapies are stabilized, manufactured, and distributed. At its core, BoSS addresses a foundational bottleneck in the delivery of advanced cell and gene therapies (CGTs): the critical dependence on ultra-cold conditions (-80 to -196˚C) for storage and transport. BoSS will yield a bioprocessing system that enables scalable production of thermally stable cells, paving the way for a new era of efficient and resilient manufacturing and distribution of biologics without any need for cold storage. BoSS-developed technologies will also accelerate many other avenues in biotechnology that directly impact healthcare, including bio-surveillance, regenerative medicine, large-scale genetic testing, blood product supply, and wound repair, in addition to improving access to a wide range of existing biotherapeutics.

Solution Summaries are required:

For consideration as a Performer:

• Solution Summary due date: February 19th, 2026 5:00 PM ET

For consideration as an IV&V partner:

• Solution Summary due date: April 17th, 2026 5:00 PM ET

Interested parties are invited to review the attached BoSS Innovative Solutions Opening (ISO) ARPA-H -SOL-26-136.

Submissions must be made to:

• Solution Summary Submission Site: https://solutions.arpa-h.gov/Submit-Solution/

Please ensure to follow this opportunity for any updates.

For more information on the BoSS program visit: https://arpa-h.gov/explore-funding/programs/boss.

For information on Proposer's Day details and registration information, please see Special Notice ARPA-H-SN-26-137.